Cargando…

Single‐cell profiling‐guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma

BACKGROUND: Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma. Histone deacetylase inhibitors (HDACis) have been widely applied in multiple tumours, but the expected efficacy was not observed in DLBCL. Therefore, this study is aimed to explore superior HDACis a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Luqiao, Wu, Zijuan, Xia, Yi, Lu, Xueying, Li, Ji, Fan, Lei, Qiao, Chun, Qiu, Hairong, Gu, Danling, Xu, Wei, Li, Jianyong, Jin, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076017/ https://www.ncbi.nlm.nih.gov/pubmed/35522945 http://dx.doi.org/10.1002/ctm2.798

Ejemplares similares

Single‐cell profiling guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma
por: Krämer, Oliver H., et al.
Publicado: (2022)

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
por: Zhang, Qing, et al.
Publicado: (2019)

Expression of Histone Deacetylases in Diffuse Large B-cell Lymphoma and Its Clinical Significance
por: Lee, Sung Hak, et al.
Publicado: (2014)

The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma
por: Dias, Joana N.R., et al.
Publicado: (2018)

Increased histone deacetylase 6 expression serves as a favorable prognostic factor for diffuse large B-cell lymphoma
por: Lin, Xiao-Ji, et al.
Publicado: (2017)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

CircRIC8B regulates the lipid metabolism of chronic lymphocytic leukemia through miR199b-5p/LPL axis
por: Wu, Zijuan, et al.
Publicado: (2022)

Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
por: Lu, Guang, et al.
Publicado: (2023)

The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms
por: Cai, Ying, et al.
Publicado: (2013)

Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma
por: Kim, Soo Jin, et al.
Publicado: (2020)

A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors
por: Tula-Sanchez, Ana A, et al.
Publicado: (2013)

Histone deacetylase 6 activity is critical for the metastasis of Burkitt’s lymphoma cells
por: Ding, Ning, et al.
Publicado: (2014)

Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib‐resistant chronic lymphocytic leukaemia
por: Wu, Zijuan, et al.
Publicado: (2022)

The Sensitivity of Diffuse Large B-Cell Lymphoma Cell Lines to Histone Deacetylase Inhibitor-Induced Apoptosis Is Modulated by BCL-2 Family Protein Activity
por: Thompson, Ryan C., et al.
Publicado: (2013)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Paradoxical Regulation of Hypoxia Inducible Factor-1α (HIF-1α) by Histone Deacetylase Inhibitor in Diffuse Large B-Cell Lymphoma
por: Bhalla, Savita, et al.
Publicado: (2013)

Inhibition of Notch Signaling Enhances Antitumor Activity of Histone Deacetylase Inhibitor LAQ824
por: Mei, Qinglang, et al.
Publicado: (2023)

Histone Deacetylase Inhibition: An Important Mechanism in the Treatment of Lymphoma
por: Guo, Shan-qi, et al.
Publicado: (2012)

Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma
por: Wells, Christina E., et al.
Publicado: (2013)

Recalcitrant Subcutaneous Panniculitis-Like T-Cell Lymphoma Responsive to Histone Deacetylase Inhibitor
por: Gleason, Laura, et al.
Publicado: (2022)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors
por: Zheng, Zhong, et al.
Publicado: (2014)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma
por: Dong, Li Hua, et al.
Publicado: (2013)

The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines
por: Cosenza, Maria, et al.
Publicado: (2016)

Genome-wide identification of alternative splicing associated with histone deacetylase inhibitor in cutaneous T-cell lymphomas
por: Yu, Shirong, et al.
Publicado: (2022)

Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition
por: Winkler, René, et al.
Publicado: (2022)

Role of Histone Deacetylases in T-Cell Development and Function
por: Pieniawska, Monika, et al.
Publicado: (2022)

Statins and Histone Deacetylase Inhibitors Affect Lamin A/C – Histone Deacetylase 2 Interaction in Human Cells
por: Mattioli, Elisabetta, et al.
Publicado: (2019)

Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
por: Freese, Kim, et al.
Publicado: (2019)

Quantitative Acetylomics Uncover Acetylation-Mediated Pathway Changes Following Histone Deacetylase Inhibition in Anaplastic Large Cell Lymphoma
por: Zrimšek, Maša, et al.
Publicado: (2022)

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
por: Marquard, L, et al.
Publicado: (2008)

Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy
por: Haery, Leila, et al.
Publicado: (2015)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets
por: Miao, Yi, et al.
Publicado: (2019)

The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines
por: Klein, Jan M., et al.
Publicado: (2013)

Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming
por: Kretsovali, Androniki, et al.
Publicado: (2012)

Dendritic cell development requires histone deacetylase activity
por: Chauvistré, Heike, et al.
Publicado: (2014)

Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells
por: Wawruszak, Anna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_898s03utrloh8f319iap645sha